← Eichor
Condition: Btc Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Btc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN
NA · 2 location(s) · Nantes University Hospital · NCT06735560ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer
Phase N/A · 1 location(s) · CHA University · NCT07151118Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC
Phase N/A · 1 location(s) · CHA University · NCT07142226AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metasta
Phase 1/Phase 2 · 18 location(s) · Avenzo Therapeutics, Inc. · NCT07038343Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
Phase 2 · 1 location(s) · Columbia University · NCT07433673A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Phase 1 · 6 location(s) · SEED Therapeutics, Inc. · NCT07197554Surgical Total Clearance Versus Extrahepatic Bile Duct Preservation for Biliary Tract Malignancies: A Single-Center, Ran
NA · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07609641Cosiporfin Sodium for Injection Photodynamic Therapy
Phase 2 · 1 location(s) · Shanghai Guangsheng Biopharmaceutical Co., Ltd · NCT07398339Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer
Phase N/A · 1 location(s) · CHA University · NCT06893380Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Phase 1 · 21 location(s) · I-Mab Biopharma US Limited · NCT04900818A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Phase 2 · 8 location(s) · Nanjing Leads Biolabs Co.,Ltd · NCT07111546CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents W
Phase 2/Phase 3 · 19 location(s) · Gruppo Oncologico del Nord-Ovest · NCT06037980Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Biliary Tract Cancer Recurrence Surveillance
Phase N/A · 1 location(s) · Tongji Hospital · NCT06653127Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
Phase 1 · 1 location(s) · Shanghai Zhongshan Hospital · NCT07614061GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）
Phase N/A · 1 location(s) · Fudan University · NCT06988592In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Techno
Phase N/A · 1 location(s) · University of Nottingham · NCT07206355A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · 24 location(s) · DualityBio Inc. · NCT05785741A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects W
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05849480Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07159204Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Phase 1/Phase 2 · 4 location(s) · Yuhan Corporation · NCT06975410Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
Phase 3 · 21 location(s) · Taiho Pharmaceutical Co., Ltd. · NCT07710885A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 6 location(s) · Pliant Therapeutics, Inc. · NCT06270706A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Bilio
Phase N/A · 1 location(s) · Tongji Hospital · NCT07326137D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
Phase 3 · 3 location(s) · InnoPharmax Inc. · NCT06622057A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers
NA · 1 location(s) · Jiangsu Healthy Life Innovation Medical Technology Co., Ltd · NCT06611345Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Phase 2 · 12 location(s) · Replimune, Inc. · NCT05733598A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in
Phase 3 · 1 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07229625Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07726446HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
NA · 2 location(s) · Peking University · NCT07466238A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumo
Phase N/A · 14 location(s) · AstraZeneca · NCT07404202
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.